AI assistant
Ambu Share Issue/Capital Change 2018
3353_rns_2018-02-09_b261ec6f-1d14-447a-9131-fec86cb59ffe.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Ambu
Ideas that work for life
Capital increase in connection with exercise of warrants
In December 2014, Ambu A/S issued 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. These warrants were issued to 22 employees with a vesting period of three years and may therefore be exercised in the trading window, which was opened on 31 January 2018 in connection with Ambu's interim financial report for Q1 2017/18.
Today eight employees have given instruction as to the exercise of 960,000 warrants to the agreed exercise price of 23.06 per B-share at a nominal value of DKK 0.50 and at the same time the Board of Directors of Ambu passed a resolution to carry out the capital increase relating to the warrants exercised.
As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 480,000 from DKK 124,912,300 to DKK 125,392,300 through the issue of 960,000 Class B shares.
Following this exercise of warrants and in consideration of the employees having left the company, 940,000 remaining warrants relating to the 2014 scheme are now being held by 12 individuals.
The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 14 February 2018 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).
Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.
| Number of shares (nominal value DKK 0.50) | Nominal value (DKK) | Voting rights | |
|---|---|---|---|
| A shares | 34.320,000 | 17,160,000 | 343,200,000 |
| B shares | 216,464,600 | 108,232,300 | 216,464,600 |
| Total | 250,784,600 | 125,392,300 | 559,664,600 |
Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: [email protected]
About Ambu
Since 1937, breakthrough ideas have driven our work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and advancing single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ and the legendary Blue Sensor™ electrodes to our latest landmark solutions such as the aScope™ – the world's first flexible single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu employs approximately 2,500 people in Europe, North America, Asia and the Pacific region. You can find more information about Ambu at www.ambu.com
Ambu
Company announcement no. 17-2017/18
9 February 2018